Anti a–syn antibody / AC Immune - LARVOL DELTA

AC Immune Awarded Two Michael J. Fox Foundation Grants to Advance Small Molecule Parkinson’s Disease Programs (GlobeNewswire) - "AC Immune SA...today announced it has been awarded two grants, a total of approximately USD 1.5 million, from The Michael J. Fox Foundation for Parkinson’s Research (MJFF), to develop first-in-class brain penetrant small molecules targeting alpha-synuclein (a-syn) and the (NOD)-like receptor protein 3 (NLRP3) inflammasome pathway in Parkinson’s disease (PD)....The awarded programs complement AC Immune’s portfolio in PD, which covers the full spectrum of treatment modalities addressing a-syn, a well-characterized target in PD. It includes the Phase 2 ready anti-a-syn vaccine ACI-7104, as well as a next-generation positron emission tomography (PET) imaging tracer. AC Immune’s PD portfolio also includes a pre-clinical stage anti-a-syn antibody..."

Financing • CNS Disorders • Parkinson's Disease

AC Immune reports Q1 2020 financial results and provides business update (GlobeNewswire) - "Advanced a lead anti-alpha-synuclein therapeutic antibody candidate into preclinical development based on new proof-of-concept data presented at AAT-AD/PD^TM....2020 Preclinical Milestones: Alpha-synuclein antibody: started investigational new drug (IND)-enabling studies for lead candidate in Q1 (achieved); Anti-TDP-43 antibody: declare clinical lead and start IND-enabling studies in Q2; Alpha-synuclein small molecule: identify first biologically active small molecule in Q2; Alpha-synuclein imaging agent: advance third generation candidate to clinical stage in Q4."

IND • New molecule • Preclinical • CNS Disorders • Parkinson's Disease • Tauopathies And Synucleinopathies

AC Immune presents the latest preclinical data on novel drug targets for neurodegenerative diseases (GlobeNewswire, AC Immune SA) - "AC Immune SA...today outlined new preclinical data that will be presented at this year’s first ever online AAT-AD/PD™ Focus Meeting from April 2–5, 2020. The presentations describe proof-of-concept preclinical data for lead candidates in AC Immune’s therapeutic and diagnostic programs targeting TDP-43 and alpha-synuclein; A lead anti-alpha-synuclein therapeutic antibody candidate has advanced into preclinical development to treat Parkinson’s disease and other synucleinopathies."

Biomarker • Clinical data • Preclinical

AC Immune Presents New Data on Alpha-Synuclein PET Tracer at AD/PD™ Conference (GlobeNewswire, AC Immune SA) - "AC Immune SA...today announced new data on its positron-emission tomography (PET) tracer, which demonstrated a high-affinity binding to human Parkinson’s disease-brain derived alpha-synuclein (a-syn), potentially capable of accurately detecting and monitoring progression of Parkinson’s disease (PD) in humans....CEO of AC Immune SA, commented: 'These data show the potential for what may be the first PET tracer for PD, which we are now moving into a Phase 1 trial'....The company also is beginning preclinical development of oral small molecule Morphomer a-syn inhibitors and SupraAntigenTM a-syn antibodies as novel therapeutic candidates to treat PD and a-syn-related NeuroOrphan diseases."

P1 data • Preclinical